Purespring Therapeutics to Showcase Its Innovative Approach
Purespring Therapeutics, a pioneering precision nephrology company, has made significant strides in developing groundbreaking genetic therapies aimed at preserving kidney function. Recently, the company announced its participation in a key healthcare event, the Piper Sandler’s 37th Annual Healthcare Conference. This event will take place from December 2 to December 4 in New York.
Details About the Conference
During the Piper Sandler Healthcare Conference, Purespring will have the opportunity to present its novel approaches and findings. The management team is scheduled to speak on December 3 at 3:30 PM ET, highlighting the advancements in their therapeutic techniques.
About Purespring’s Groundbreaking Work
Purespring is at the forefront of precision nephrology, developing first-in-class genetic therapies specifically designed for renal health. Utilizing their proprietary GlomThera™ platform, the company focuses on targeted delivery of genetic therapies directly to kidney cells known as podocytes. This innovative method represents a significant shift in how kidney diseases are treated.
Focus on Renal Health and Innovative Therapies
The company is committed to addressing renal diseases with a strong pipeline aimed at various conditions that currently suffer from a lack of effective treatments. Notably, Purespring’s leading program, PS-002, targets IgA nephropathy (IgAN), a condition with substantial unmet medical needs. The strategic focus on the precise location of the disease aims to change the prognosis for many patients.
A Strong Foundation and Future Plans
Purespring Therapeutics enjoys robust backing from prominent biotech investors such as Syncona Limited and Forbion, having successfully raised £115 million (approximately $150 million) to propel its research and development efforts. This strong financial foundation allows Purespring to forge ahead with its innovative therapies.
For Inquiries and Further Information
For those interested in reaching out to Purespring, inquiries can be directed via email. The contact point for the company is: contact@purespringtx.com, and they can also be contacted by phone at +44 (0)20 3855 6324. Additional information about their pioneering work can also be found on their official website.
Frequently Asked Questions
What is Purespring Therapeutics known for?
Purespring Therapeutics is known for developing targeted genetic therapies to preserve kidney function, specifically leveraging their GlomThera™ platform.
What is the significance of the Piper Sandler Conference?
The Piper Sandler Conference is a critical event where Purespring will present its latest developments and network with industry leaders in healthcare.
What is the lead program of Purespring?
The lead program, PS-002, focuses on treating IgA nephropathy, aiming to transform patient outcomes through targeted treatment approaches.
Who are Purespring's key investors?
Purespring has received funding from notable investors such as Syncona Limited and Forbion, which supports their innovation and development initiatives.
How can I contact Purespring for more information?
Individuals can reach out to Purespring via email at contact@purespringtx.com or by calling +44 (0)20 3855 6324 for inquiries.